Everything you need to know about the latest CSL dividend

The CSL Limited (ASX: CSL) share price is backtracking 1.24% to $292.73 today following the release of the company’s full-year results.

The biotherapeutics company reported a mixed performance due to a “difficult global environment.”

Nonetheless, the result was in line with expectations, achieving the top end of its guidance.

Here’s a look at the CSL’s latest dividend that was announced to the market.

CSL maintains full-year dividend

After delivering a net profit after tax (NPAT) of $2,255 million in FY22, the CSL board declared a final dividend of US$1.18 per share.

When converted to the Australian currency, this reflects an approximate dividend of $1.68 per share, franked at 10%.

Moreover, despite CSL maintaining its full-year dividend of US$2.22 apiece, this is 6% higher due to favourable currency movements.

The full-year dividend is equivalent to 46.2% of the group’s basic earnings per share (EPS) of US$4.81.

You still have time to scoop up the latest dividend as the ex-dividend date falls on 6 September.

CSL will pay the distribution of its profits to eligible shareholders on 5 October.

What about the FY23 dividend?

While CSL didn’t give any guidance on its dividend for FY23, we take a look at what Goldman Sachs had to say.

The broker released its key takeaways on the back of CSL’s FY22 results.

It said “NPAT is guided to $2.4bn-2.5bn, excluding Vifor (constant currency terms). Consensus expectations are heavily distorted by the impact of Vifor in our view, but our best guess at ‘organic CSL’ consensus is $2.575bn.”

Upside risks included: More supportive pricing dynamic than we already expect, positive results from pipeline/pre-commercialisation products, and plasma donor fee deflation.

However, downside risks involved: Competitive product launches, challenges associated with unemployment/payer mix, and sustained challenges due to COVID-19.

Goldman Sachs has a neutral rating on CSL with a 12-month target price of $307 per share.

CSL share price snapshot

Over the last 12 months, the CSL share price experienced volatility on the back of an uncertain global economic outlook.

After touching a 52-week low of $240.10 on 15 February, its shares hit resistance at around the $270 mark.

Since then, that barrier has been breached with CSL shares trading around 4% under the psychological $300 level.

Based on today’s price, CSL commands a market capitalisation of $141 billion and has a trailing dividend yield of 1.03%.

The post Everything you need to know about the latest CSL dividend appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• An ASX 200 market darling in the past, but don’t expect fireworks from the CSL share price going forward
• CSL share price drops despite expectations of growth in FY23
• CSL share price on watch following FY22 results
• 5 things to watch on the ASX 200 on Wednesday
• Looking to buy CSL shares? Here’s what to watch when the biotech company reports this week

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/6XKmyGb